Aspect Medical Systems Provides Commentary at FDA Meeting about Preclinical Neurotoxicity of Anesthetic Drug Products.

NORWOOD, Mass. -- Aspect Medical Systems, Inc. (NASDAQ: ASPM) Vice President of Medical Affairs, Scott Kelley, MD, presented comments today at an open public hearing conducted in Washington, DC as part of a Food and Drug Administration (FDA) meeting about the preclinical neurotoxicity of anesthetic drug products. The meeting was convened by the Anesthetic and Life Support Drugs Advisory Committee of the FDA to review preclinical presentations regarding studies conducted in juvenile animals that indicate neurodegenerative effects from exposure to anesthetic drugs. Meeting participants discussed these presentations and their implications for the practice of anesthesia and the need for further preclinical and clinical studies. Dr. Kelley's comments and presentation are available for viewing on the Aspect Medical Systems Web site at http://www.aspectmedical.com/. More information about the FDA advisory committee is available at http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4285b1-01.pdf.

About Aspect Medical Systems, Inc.

Aspect Medical Systems, Inc. (NASDAQ: ASPM) is a global market leader in brain monitoring technology. To date, the Company's Bispectral Index (BIS) technology has been used to assess more than 18.7 million patients and has been the subject of approximately 2,710 published articles and abstracts. BIS technology is installed in approximately 73 percent of hospitals listed in the July 2006 U.S. News and World Report Ranking of America's Best Hospitals and in approximately 53 percent of all domestic operating rooms. In the last twelve months BIS technology was used in approximately 16 percent of all U.S. surgical procedures requiring general anesthesia or deep sedation. BIS technology is available in more than 160 countries. Aspect Medical Systems has OEM agreements with seven leading manufacturers of patient monitoring systems. The company is also investigating how other methods of analyzing brain waves may aid in the diagnosis and management of neurological diseases, including depression and Alzheimer's disease. For more information, visit Aspect's Web site at http://www.aspectmedical.com.

Safe Harbor Statement

Certain statements in this release are forward-looking and may involve risks and uncertainties. There are factors that could cause the Company's actual results to vary from its forward-looking statements, including without limitation those set forth under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2006, as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent the Company's views only as of the date of this press release and should not be relied upon as representing the Company's views as of any subsequent date. While the Company may elect to update forward-looking statements in the future, it specifically disclaims any obligation to do so, even if its expectations change. Therefore, you should not rely on these forward-looking statements as representing the Company's views as of any date subsequent to the date of this press release.

Aspect, Bispectral Index and BIS are registered trademarks of Aspect Medical Systems, Inc. All other trademarks, service marks and company names are the property of their respective owners.